Study consists of an eight day inpatient visit on the General Clinical Research Center. The
investigators' specific aims are to:
1. To define the maximum safe dose of a seven day continuous administration of parathyroid
hormone [PTH(1-34)] in healthy human volunteers.
2. To estimate the effect of a seven day continuous administration of parathyroid Hormone
(PTH) in escalating doses on vitamin D metabolism, markers of bone turnover and
fractional excretion of urine.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)